Please login to the form below

Not currently logged in
Email:
Password:

Diabetes drug development data announced

Boehringer's linagliptin demonstrates reduction of blood glucose in phase III as Novo Nordisk's degludec achieves proof-of-concept at phase II

Boehringer Ingelheim's linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor under investigation as a once-daily oral treatment against type 2 diabetes, achieved clinically meaningful reductions in blood glucose, according to phase III study data presented at the 70th Scientific Sessions of the American Diabetes Association (ADA).

In four multicentre, 24-week, randomised, double-blind trials, linagliptin's blood glucose reductions were significant versus placebo and sustained over the study periods. The compound, which has a primarily non-renal route of excretion, is being investigated as a monotherapy and in combination with metformin, with pioglitazone and with voglibose, which is not licensed in the UK.

Also at the ADA meeting, Novo Nordisk presented phase II proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycaemic control (similar to insulin glargine) when used once-daily or three-times-weekly.

Insulin degludec, a novel insulin molecule with a distinct ultra-long clinical profile, is believed to slow the absorption rate of the insulin into the blood. This leads to a longer profile of action and the possibility of a three-times-weekly dosing regimen in patients with type 2 diabetes. Insulin degludec will now be investigated in the pivotal phase III BEGIN and BOOST trials.

28th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health offers a unique breadth and depth of experience, across everything from early stage product commercialisation, strategy and research,...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics